title: Bioavailability of a crushed pantoprazole tablet after buffering with sodium hydrogencarbonate or magaldrate relative to the intact enteric coated pantoprazole tablet.
abstract: The aim of this study was to determine the bioavailability of orally administered, crushed pantoprazole tablets after buffering with either 1.4% sodium hydrogencarbonate or 1600 mg magaldrate relative to the intact enteric coated pantoprazole tablet. A single dose, three-period crossover study was performed with 18 healthy male volunteers. The crushed pantoprazole suspension, together with either sodium hydrogencarbonate or magaldrate, was administered via a nasogastral tube. Tmax of crushed pantoprazole was earlier as compared to the intact tablet (0.5 h vs. 3 h) and Cmax was approximately 10% higher due to faster absorption. The bioavailability of the crushed pantoprazole tablet relative to the intact pantoprazole tablet was 93% when using sodium hydrogencarbonate as the buffering agent, and 88% when using magaldrate. Based on the internationally approved confidence intervals for AUC (0.80-1.20) and Cmax (0.70-1.43), the crushed tablet buffered with sodium hydrogencarbonate was shown to be bioequivalent with the intact tablet (point estimates for AUC or Cmax: 0.93 or 1.10). For the crushed tablet buffered with magaldrate (point estimates for AUC or Cmax: 0.88 or 1.12) bioequivalence with the intact tablet could not be formally demonstrated, although the lower confidence limit for AUC of 0.78 was only slightly below the lower limit of the equivalence range of 0.80.
authors: Institut für klinische Pharmakologie Bobenheim, Grünstadt, Germany. ley@ikp.de
authors: L M
authors: LM
authors: Ley
authors: B
authors: B
authors: Stahlheber-Dilg
authors: P
authors: P
authors: Sander
authors: R
authors: R
authors: Huber
authors: H
authors: H
authors: Mascher
authors: P W
authors: PW
authors: Lücker
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000536:Aluminum Hydroxide / Q000494:pharmacology*; D000863:Antacids / Q000494:pharmacology*; D000897:Anti-Ulcer Agents / Q000097:blood / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001562:Benzimidazoles / Q000097:blood / Q000493:pharmacokinetics*; D001682:Biological Availability; D002021:Buffers; D004347:Drug Interactions; D006207:Half-Life; D006801:Humans; D008276:Magnesium Hydroxide / Q000494:pharmacology*; D008297:Male; D009853:Omeprazole / Q000031:analogs & derivatives; D000077402:Pantoprazole; D017693:Sodium Bicarbonate / Q000494:pharmacology; D013454:Sulfoxides / Q000097:blood / Q000493:pharmacokinetics*; D013608:Tablets, Enteric-Coated
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000863:Antacids; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D002021:Buffers; D013454:Sulfoxides; D013608:Tablets, Enteric-Coated; D000536:Aluminum Hydroxide; C016545:magaldrate; D017693:Sodium Bicarbonate; D000077402:Pantoprazole; D009853:Omeprazole; D008276:Magnesium Hydroxide